Skip to content
Parakho

Bal Pharma Ltd

NSE BALPHARMABSE 524824

Q1 FY27, unaudited

Revenue
₹88.43 Cr
Profit after tax
₹1.16 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations88.43+34.73%310.80
Other income0.46−38.32%2.00
Total income88.88+33.91%312.80
Employee benefit expense16.93+15.39%65.92
Finance costs4.47+10.21%16.81
Depreciation & amortisation2.78+10.45%11.06
Total expenses87.72+32.81%306.43
Profit before tax1.16+259.11%6.37
Tax expense0.00—-0.39
Profit after tax1.16+259.11%6.75
Total comprehensive income1.16+259.11%7.19
Earnings per share
Earnings per share, basic₹0.73₹4.27
Earnings per share, diluted₹0.73₹4.27

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Bal Pharma Ltd has not filed a concall transcript in the last 4 quarters.

Filings

12 shown · 34 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 07 Oct 2026.